EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology
Proceeds advance multiple programs, including EPI-326 into first-in-human clinical trial in early 2026 for EGFR-driven lung cancer and head and neck cancer SAN MATEO, Calif.–(BUSINESS WIRE)–EpiBiologics, a leader in tissue-selective extracellular protein degradation, today announced the…